We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
We are committed to bringing more of our medicines to more people, no matter where they are.
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
Novartis Financial Results – Q2 2022
Novartis announced the company’s financial results for the second quarter and first half of 2022.
Novartis COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.